Thymidylate Synthase 5’ UTR Polymorphic Allele Distribution in South Florida Population
- 1 Department of Biology, Miller School of Medicine, University of Miami, Miami, USA
- 2 Department of Biology, Miller School of Medicine, University of Miami, Miami, USA
- 3 Department of Medicine, Division of Hematology and Oncology, Miller School of Medicine, University of Miami, Miami, USA.
- 4 Department of Medicine, Division of Hematology and Oncology, Miller School of Medicine, University of Miami, Miami, USA
Abstract
Thymidylate synthase (TS; TYMS) is a pivotal enzyme in the DNA synthesis pathway. The 5’UTR of TYMS gene has a polymorphic 28 bp segment. Presence of two or three repeats of this unique 28 bp sequence is common. A distinct population distribution pattern for this polymorphic trait among different racial groups had been reported. We analyzed TYMS genotype in the peripheral blood mononucleocytes (PBMC) of 74 individuals in the South Florida region of the United States of America. The number of 28 bp repeats in the 5’ UTR was determined by PCR followed by agarose gel electrophoresis. The distribution of the three different genotypes was found to be 35.1% for 2R/2R, 39.2% for 2R/3R and 24.3% for 3R/3R. One individual was detected with 3R/4R genotype. Functional analyses associated homozygous for three repeats (3R/3R) to higher TYMS expression and therefore poor prognosis to chemotherapy. The other possible genotypes viz 2R/2R or 2R/3R is proposed to have better prognosis. However, there are reports that challenge this observation.
- F. Innocenti and M. J. Ratain, “Update on Pharmacogenetics in Cancer Chemotherapy,” European Journal of Cancer, Vol. 38, No. 5, 2002, pp. 639-644. doi:10.1016/S0959-8049(01)00434-8
- H. L. McLeod and W. E. Evans, “Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy,” Annual Review of Pharmacology and Toxicology, Vol. 41, No. 1, 2001, pp. 101-121. doi:10.1146/annurev.pharmtox.41.1.101
- Y. M. Rustum, “Thymidylate Synthase: A Critical Target in Cancer Therapy?” Frontiers in Bioscience, Vol. 9, 2004, pp. 2467-2473. doi:10.2741/1408
- S. Kaneda, K. Takeishi, D. Ayusawa, K. Shimizu, T. Seno and S. Altman, “Role in Translation of a Triple Tandemly Repeated Sequence in the 5’-Untranslated Region of Human Thymidylate Synthase mRNA,” Nucleic Acids Research, Vol. 15, No. 3, 1987, pp. 1259-1270. doi:10.1093/nar/15.3.1259.
- S. Marsh, M. M. Ameyaw, J. Githanga, A. Indalo, D. Ofori-Adjei and H. L. McLeod, “Novel Thymidylate Synthase Enhancer Region Alleles in African Populations,” Human Mutation, Vol. 16, No. 6, 2000, p. 528. doi:10.1002/1098-1004(200012)16:6 3.0.CO;2-W
- N. Horie, H. Aiba, K. Oguro, H. Hojo and K. Takeishi, “Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5’-Terminal Regulatory Region of the Human Gene for Thymidylate Synthase,” Cell Structure and Function, Vol. 20, No. 3, 1995, pp. 191-197. doi:10.1247/csf.20.191
- S. Popat, A. Matakidou and R. S. Houlston, “Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis,” American Society of Clinical Oncology, Vol. 23, No. 9, 2004, pp. 529-536. doi:10.1200/JCO.2004.05.064.PMid:14752076
- B. Iacopetta, F. Grieu, D. Joseph and H. Elsaleh, “A PolyMorphism in the Enhancer Region of the Thymidylate Synthase Promoter Influences the Survival of Colorectal Cancer Patients Treated with 5-Fluorouracil,” British Journal of Cancer, Vol. 85, No. 6, 2001, pp. 827-830. doi:10.1054/bjoc.2001.2007.
- P. R. Subbarayan, M. Sarkar and B. Ardalan, “Isolation of Genomic DNA from Human Whole Blood,” BioTechniques, Vol. 33, No. 6, 2002, pp. 1231-1234.
- S. Kaneda, J. Nalbantoglu, K. Takeishi, K. Shimizu, O. Gotoh, T. Seno, et al., “Structural and Functional Analysis of the Human Thymidylate Synthase Gene,” The Journal of Biological Chemistry, Vol. 265, No. 33, 1990, pp. 20277-20284.
- H. Hammad, M. Sarkar, N. Gupta, B. Ardalan and P. R. Subbarayan, “The Presence of Three Repeats in the 5’UTR Region of Thymidylate Synthase (TS) Is Associated with Increased TS mRNA Expression in Cultured Human Cancer Cell Lines in Vitro,” Oncology Reports, Vol. 27, No. 1, 2012, pp. 246-249.